Arizona Tribune - CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

NYSE - LSE

CMSD	-0.34%	20.69	$
BCC	2.64%	79.21	$
RIO	0.42%	103.27	$
BCE	-0.59%	23.67	$
CMSC	-0.53%	20.81	$
AZN	-1.27%	162.7	$
GSK	-1.96%	49.89	$
JRI	-0.58%	12.14	$
RBGPF	0%	70	$
RELX	-3.21%	35.51	$
NGG	-0.06%	78.12	$
BTI	-1.12%	55.35	$
RYCEF	0.7%	19.92	$
VOD	1.89%	16.9	$
BP	0.52%	43.81	$

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

BOULEVARD 18.11.2024

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29^th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX.

Text size:

Details of the presentation are as follows:

Title:Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs. Lomustine After First-Line Therapy for Glioblastoma Multiforme (GBM)
Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals
Program Code: CTNI-68
Category: Poster and Networking Session
Date and Time: Friday , November 22, 2024 from 7:30 - 9:30 PM CT
Location: Hall B3, George R Brown Convention Center

For more information about SNO 2024, please visit the conference website.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.

CONTACTS:

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]

SOURCE: CNS Pharmaceuticals, Inc.

N.Walker--AT

Arizona Tribune - CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

Featured

'Truly scared': Blazes outpace firefighters in Indonesian Borneo

Sobering reality: Curbs on alcohol in northeast Syria cause discontent

'Like a jewel': Japan's luxury ice revered by bars worldwide

Commemoration held for late Bosnian Serb war criminal Ratko Mladic